STOCK TITAN

Unicycive: Vivo reports 3.91M shares if fully converted

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Unicycive Therapeutics, Inc. (UNCY) ownership amendment reports that Vivo Opportunity Fund Holdings, L.P. and its general partner, Vivo Opportunity, LLC, each beneficially own 3,911,375 shares of common stock issuable upon full conversion of Series A-3, A-4 and A-5 preferred stock underlying Tranche A, B and C warrants exercisable within 60 days. Vivo Opportunity Cayman Fund, L.P. and its general partner, Vivo Opportunity Cayman, LLC, each report 394,884 shares on the same basis.

Each reporting person reports 9.99% of the class. The share counts assume full conversion and do not give effect to provisions barring conversion if it would result in the holder owning more than 9.99% of UNCY’s voting securities.

Common shares issuable upon full conversion 3,911,375 shares Reported by Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity, LLC; the figure does not give effect to the blocking provisions.
Common shares issuable upon full conversion 394,884 shares Reported by Vivo Opportunity Cayman Fund, L.P. and Vivo Opportunity Cayman, LLC; the figure does not give effect to the blocking provisions.
Reported percentage of class 9.99% Reported by each reporting person; preferred-stock conversion is blocked if it would result in ownership above 9.99% of voting securities.
Series A-3 Convertible Preferred Stock technical
"shares of Series A-3 Convertible Preferred Stock"
Tranche A Warrants technical
"underlying Tranche A Warrants exercisable within 60 days"
beneficially owned financial
"Aggregate Amount Beneficially Owned"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
blocking provisions technical
"do not give effect to the blocking provisions"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many UNCY shares does Vivo report beneficially owning?

Vivo Opportunity Fund Holdings, L.P. and its general partner, Vivo Opportunity, LLC, each report 3,911,375 shares issuable upon full conversion; Vivo Opportunity Cayman Fund, L.P. and its general partner, Vivo Opportunity Cayman, LLC, each report 394,884 shares on the same basis.

What limits conversion of Vivo’s UNCY preferred stock?

The preferred-stock provisions bar conversion if it would result in the holder obtaining more than 9.99% of UNCY’s voting securities. The reported common-share counts assume full conversion and do not give effect to those provisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





90466Y202

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The number, as of the filing date, represents (i) 1,162,841 shares of common stock, par value $0.001 per share (the "Common Stock") of Unicycive Therapeutics, Inc. (the "Issuer") issuable upon conversion of 627.934032 shares of Series A-3 Convertible Preferred Stock, par value $0.001 per share (the "Series A-3 Preferred Stock") underlying Tranche A Warrants that are exercisable within 60 days of this Statement, (ii) 1,057,129 shares of Common Stock issuable upon conversion of 623.705756 shares of Series A-4 Convertible Preferred Stock, par value $0.001 per share (the "Series A-4 Preferred Stock") underlying Tranche B Warrants that are exercisable within 60 days of this Statement, and (iii) 1,691,405 shares of Common Stock issuable upon conversion of 1,251.639330 shares of Series A-5 Convertible Preferred Stock, par value $0.001 per share (the "Series A-5 Preferred Stock") underlying Tranche C Warrants that are exercisable within 60 days of this Statement. All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock contain provisions preventing such Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock from being converted if such conversion would result in the holder obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon conversion of the Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock in full, and do not give effect to the blocking provisions.


SCHEDULE 13G




Comment for Type of Reporting Person: The number, as of the filing date, represents (i) 1,162,841 shares of Common Stock of the Issuer, issuable upon conversion of 627.934032 shares of Series A-3 Convertible Preferred Stock underlying Tranche A Warrants that are exercisable within 60 days of this Statement, (ii) 1,057,129 shares of Common Stock issuable upon conversion of 623.705756 shares of Series A-4 Convertible Preferred Stock underlying Tranche B Warrants that are exercisable within 60 days of this Statement, and (iii) 1,691,405 shares of Common Stock issuable upon conversion of 1,251.639330 shares of Series A-5 Convertible Preferred Stock underlying Tranche C Warrants that are exercisable within 60 days of this Statement. All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock contain provisions preventing such Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock from being converted if such conversion would result in the holder obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon conversion of the Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock in full, and do not give effect to the blocking provisions.


SCHEDULE 13G




Comment for Type of Reporting Person: The number, as of the filing date, represents (i) 117,398 shares of Common Stock of the Issuer, issuable upon conversion of 63.39492 shares of Series A-3 Convertible Preferred Stock underlying Tranche A Warrants that are exercisable within 60 days of this Statement, (ii) 106,725 shares of Common Stock issuable upon conversion of 62.96775 shares of Series A-4 Convertible Preferred Stock underlying Tranche B Warrants that are exercisable within 60 days of this Statement, and (iii) 170,761 shares of Common Stock issuable upon conversion of 126.36314 shares of Series A-5 Convertible Preferred Stock underlying Tranche C Warrants that are exercisable within 60 days of this Statement. All securities are held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock contain provisions preventing such Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock from being converted if such conversion would result in the holder obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon conversion of the Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock in full, and do not give effect to the blocking provisions.


SCHEDULE 13G




Comment for Type of Reporting Person: The number, as of the filing date, represents (i) 117,398 shares of Common Stock of the Issuer, issuable upon conversion of 63.39492 shares of Series A-3 Convertible Preferred Stock underlying Tranche A Warrants that are exercisable within 60 days of this Statement, (ii) 106,725 shares of Common Stock issuable upon conversion of 62.96775 shares of Series A-4 Convertible Preferred Stock underlying Tranche B Warrants that are exercisable within 60 days of this Statement, and (iii) 170,761 shares of Common Stock issuable upon conversion of 126.36314 shares of Series A-5 Convertible Preferred Stock underlying Tranche C Warrants that are exercisable within 60 days of this Statement. All securities are held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock contain provisions preventing such Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock from being converted if such conversion would result in the holder obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon conversion of the Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock in full, and do not give effect to the blocking provisions.


SCHEDULE 13G



Vivo Opportunity Fund Holdings, L.P.
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member of Vivo Opportunity, LLC, General Partner
Date:11/16/2026
Vivo Opportunity, LLC
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member
Date:11/16/2026
Vivo Opportunity Cayman Fund, L.P.
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member of Vivo Opportunity Cayman, LLC, General Partner
Date:11/16/2026
Vivo Opportunity Cayman, LLC
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member
Date:11/16/2026

Keep reading